Table 4 Hematological and non-hematological AEs associated with ramucirumab treatment
|  | Any grade (%) | Grade ≥ 3 (%) |
|---|---|---|
Any adverse events | 38 (74%) | 7 (13%) |
Leukopenia | 4 (8%) | 0 |
Neutropenia | 9 (18%) | 0 |
Anemia | 18 (35%) | 2 (4%) |
Thrombocytopenia | 4 (8%) | 0 |
Fatigue | 19 (37%) | 1 (2%) |
Anorexia | 19 (37%) | 1 (2%) |
Hyponatremia | 1 (2%) | 1 (2%) |
Hypertension | 18 (35%) | 2 (4%) |
Proteinuria | 15 (29%) | 2 (4%) |
Thrombocytopenic events | 1 (2%) | 0 |
Bleeding | 5 (10%) | 1 (2%) |
Gastrointestinal perforation | 0 | 0 |